^
Association details:
| Biomarker: | ERBB3 expression + MUC1 expression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | DM002 (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate, MUC1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB214 / 7 - A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1
Published date:
03/15/2023
Excerpt:
DM002 candidates showed robust anti-tumor activity in multiple CDX and PDX models of lung, breast, gastric and pancreatic cancer; most notably, DM002 candidates outperformed benchmark ADCs in BP0508 lung PDX models. Together, these data indicate that DM002 will be a promising therapeutic drug for patients with HER3 and MUC1 co-expressing tumors.
